- Home
- CTAA vs NERV Comparison
CTAA vs NERV Comparison
Compare CTAA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTAA | NERV |
|---|---|---|
| Founded | 2025 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 166.4M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CTAA | NERV |
|---|---|---|
| Price | $10.01 | $2.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.33 |
| AVG Volume (30 Days) | ★ 106.8K | 105.4K |
| Earning Date | N/A | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $2.24 |
| 52 Week High | $10.10 | $8.80 |
Technical Indicators
Market Signals| Indicator | CTAA | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 27.35 |
| Support Level | $9.91 | N/A |
| Resistance Level | N/A | $5.69 |
| Average True Range (ATR) | 0.02 | 0.26 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 52.63 | 4.83 |
Price Performance
Historical ComparisonAbout CTAA ClearThink 1 Acquisition Corp. Class A Ordinary Shares
ClearThink 1 Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.